



SCHWARZWALD-BAAR
KLINIKUM
Villingen-Schwenningen
Donaueschingen



Blut- & Lymphdrüsenkrebs


Therapiefortschritt bei Leukämien, Lymphomen, Multiplen Myelom

AKADEMISCHES
LEHRKRANKENHAUS DER
UNIVERSITÄT FREIBURG



La Rosée
Patiententag_Virtuell_2020

Blutkrebs

Gesundes Blut




Akute Leukämie




Leukämie: Weisses Blut

Die Blutzellen unseres Körpers



Das Genprofil steuert die Therapieempfehlung


Mikroskopie





Zelluläre Genetik




Einzelzellanalyse (FACS)



FISH




Molekulare Genetik



Von der Gendiagnostik zur Therapie, ein steiniger Weg



2001



Gene	Overall Frequency (%)
FLT3 (ITD, TKD)	37 (30, 7)
NPM1	29
DNMT3A	23
NRAS	10
CEBPA	9
TET2	8
WT1	8
IDH2	8
IDH1	7
KIT	6
RUNX1	5
MLL-PTD	5
ASXL1	3
PHF6	3
KRAS	2
PTEN	2
TP53	2
HRAS	0
EZH2	0

2012

„Personalisierte“ Therapieempfehlungen bei AML

	1 st line therapy	Maintenance
Fit for intensive chemo	CBF	Intensive chemo + GO
	<i>FLT3</i> ^{mut}	Intensive chemo + Midostaurin
	tAML, sAML, AML MRC	CPX-351
	Alternative non-targeted option	Intensive chemo ± GO
≥75 or co-morbidities	<i>FLT3</i> -ITD	AZA ± <i>FLT3</i> i
	<i>IDH1</i> ^{mut}	AZA and/or Ivosidenib
	<i>IDH2</i> ^{mut}	AZA and/or Enasidenib
	<i>NPM1</i> ^{mut}	HMA or LDAC + Venetoclax
	Alternative non-targeted option	HMA or LDAC + Venetoclax LDAC + Glasdegib

Relapsed/refractory AML	
<i>IDH1</i> ^{mut}	Ivosidenib
<i>IDH2</i> ^{mut}	Enasidenib
<i>FLT3</i> ^{mut}	Gilteritinib
Other	Chemo ± GO




Therapieverbesserung im Deutschland-weiten Verbund

AML SG


German-Austrian
Acute Myeloid Leukemia
Study Group



Die chronische Lymphatische Leukämie (CLL)



Rituximab
Obinutuzumab




Therapie bei B-CLL: Abschied von Chemotherapie





6 Mon




6 Mon



12 Mon




Dauertherapie




12 Mon


Die Blutzellen unseres Körpers




Immuntherapie beim Multiplen Myelom: Daratumumab-Rd



Chronische Krankheitskontrolle erreichen: HD7



Maligne Lymphome & Multiples Myelom. Therapieverbesserung im Verbund



DKG
KREBSGESELLSCHAFT



DGHO
DEUTSCHE GESELLSCHAFT FÜR
HÄMATOLOGIE UND MEDIZINISCHE ONKOLOGIE



DKG
KREBSGESELLSCHAFT




Zertifiziertes
Onkologisches
Zentrum




Hämatologisches Zentrum

Was wir aus der Leukämieforschung für COVID-19 gelernt haben



COVID-19: Therapiesteuerung Im Verbund der Disziplinen



Gemeinsam die wachsenden Herausforderungen meistern



SCHWARZWALD-BAAR KLINIKUM

Vielen Dank für Ihre Aufmerksamkeit